StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kalaris Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$41.02M. For fiscal 2025 it was -$38.37M. The highest annual figure on record is -$20.16M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$38.37M–
FY2024Dec 31, 2024-$20.67M–
FY2023Dec 31, 2023-$124.45M–
FY2022Dec 31, 2022-$142.05M–
FY2021Dec 31, 2021-$106.32M–
FY2020Dec 31, 2020-$60.81M–
FY2019Dec 31, 2019-$20.16M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.05M–
Q1 FY2026Mar 31, 2026-$11.58M–
Q4 FY2025Dec 31, 2025-$7.06M–
Q3 FY2025Sep 30, 2025-$11.33M–
Q2 FY2025Jun 30, 2025-$12.54M–
Q1 FY2025Mar 31, 2025-$7.44M–
Q4 FY2024Dec 31, 2024-$7.85M–
Q3 FY2024Sep 30, 2024-$4.33M–
Q2 FY2024Jun 30, 2024-$3.97M–
Q1 FY2024Mar 31, 2024-$4.52M–
Q4 FY2023Dec 31, 2023-$30.74M–
Q3 FY2023Sep 30, 2023-$34.48M–
Q2 FY2023Jun 30, 2023-$27.12M–
Q1 FY2023Mar 31, 2023-$32.12M–
Q4 FY2022Dec 31, 2022-$31.57M–
Q3 FY2022Sep 30, 2022-$35.13M–
Q2 FY2022Jun 30, 2022-$28.88M–
Q1 FY2022Mar 31, 2022-$46.48M–
Q4 FY2021Dec 31, 2021-$28.07M–
Q3 FY2021Sep 30, 2021-$36.44M–
Q2 FY2021Jun 30, 2021-$22.89M–
Q1 FY2021Mar 31, 2021-$18.93M–
Q4 FY2020Dec 31, 2020-$21.09M–
Q3 FY2020Sep 30, 2020-$18.06M–
Q2 FY2020Jun 30, 2020-$11.12M–
Q1 FY2020Mar 31, 2020-$10.54M–
Q4 FY2019Dec 31, 2019-$8.87M–
Q3 FY2019Sep 30, 2019-$6.40M–

More Kalaris Therapeutics figures

See a number that looks wrong?